Quest Diagnostics (DGX) PT Raised to $225 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $255.64 +3.47%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
Barclays analyst Luke Sergott raised the price target on Quest Diagnostics (NYSE: DGX) to $225.00 (from $210.00) while maintaining a Overweight rating.
You May Also Be Interested In
- ONEOK Inc (OKE) PT Raised to $108 at Argus
- Flutter Entertainment (FLUT) PT Lowered to $124 at Stifel
- GlobalFoundries Inc. (GFS) PT Lowered to $50 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
